Published in BJU Int on November 01, 2010
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol (2009) 4.27
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol (2013) 2.78
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol (2010) 2.61
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol (2010) 2.27
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int (2010) 2.10
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol (2009) 1.98
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol (2010) 1.88
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol (2007) 1.87
Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol (2007) 1.84
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol (2002) 1.82
Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol (2010) 1.79
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79
A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int (2006) 1.79
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? J Urol (2010) 1.78
A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int (2008) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
Should we abandon the FISH test? Eur Urol (2007) 1.62
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Extended pelvic lymph node dissection in robotic-assisted radical prostatectomy: surgical technique and initial experience. Urology (2010) 1.57
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer (2006) 1.53
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol (2004) 1.50
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy. Eur Urol (2012) 1.50
Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria. J Urol (2008) 1.50
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol (2010) 1.48
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol (2010) 1.47
Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. J Urol (2013) 1.44
Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol (2004) 1.43
Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol (2014) 1.43
Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. J Urol (2009) 1.43
The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. Health Qual Life Outcomes (2011) 1.41
Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications. BJU Int (2011) 1.40
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU Int (2011) 1.40
Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol (2010) 1.38
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol (2006) 1.36
Metastatic renal cell carcinoma risk according to tumor size. J Urol (2009) 1.35
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int (2010) 1.32
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. J Clin Oncol (2013) 1.30
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol (2010) 1.27
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol (2008) 1.26
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol (2010) 1.26
Presacral cystic schwannoma in a man. Urology (2003) 1.21
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun (2003) 1.19
Ethnic differences in bladder cancer survival. Urology (2011) 1.17
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int (2009) 1.13
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One (2010) 1.13
Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology (2002) 1.10
Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J Urol (2003) 1.09
Quality control in transurethral resection of bladder tumours. BJU Int (2008) 1.08
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. Ann Intern Med (2014) 1.05
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol (2011) 1.05
Chronic kidney disease before and after partial nephrectomy. J Urol (2010) 1.05
Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw (2006) 1.04
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer (2010) 1.03
Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol (2009) 1.03
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol (2003) 1.03